anmelden
PTC Therapeutics Aktie
78,50
EUR
+0,64
EUR
+0,82
%
89,81
USD
+0,63
USD
+0,71
%
PTC Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
PTC Therapeutics Aktie Analyse
| 01.10.18 | PTC Therapeutics Overweight | Cantor Fitzgerald | |
| 01.03.16 | PTC Therapeutics overweight | Barclays Capital | |
| 24.02.16 | PTC Therapeutics Outperform | Wedbush Morgan Securities Inc. | |
| 16.10.15 | PTC Therapeutics Outperform | Oppenheimer & Co. Inc. | |
| 16.10.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
| 31.07.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
| 23.04.15 | PTC Therapeutics Outperform | Oppenheimer & Co. Inc. | |
| 09.04.15 | PTC Therapeutics Buy | Deutsche Bank AG | |
|
Werbung
|
|||
| 04.03.15 | PTC Therapeutics overweight | Barclays Capital | |
| 02.03.15 | PTC Therapeutics Buy | ROTH Capital Partners, LLC | |
| 23.01.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
| 29.09.14 | PTC Therapeutics Buy | ROTH Capital Partners, LLC | |
Werbung
Werbung